Aclarion Inc (ACON) Stock Forecast & Price Target

Aclarion is a healthcare technology company with a strong IP moat that recently announced new US patent covering machine-learning-based pain assessment. The company reported strong Q1 FY26 results, with a revenue increase of 11% driven by higher Nociscan report volume, but higher operating expenses led to a lower FY26 estimate. Aclarion has been investing in sales, R&D, and IR to drive commercialization and recently announced commercial agreements with Weill Cornell Medicine and Och Spine. Their available market opportunity in the US is estimated to be over $400 million per year, and the company has a strong balance sheet with $22 million in cash.

Aclarion is facing significant delays in the completion and analysis of their CLARITY trial, with initial results now expected in Q4 2026, which could potentially hinder the company's efforts to establish Nociscan as a viable treatment for chronic low back pain. While Nociscan is currently exempt from FDA approval, the CLARITY trial is crucial in providing evidence of the efficacy of the technology to physicians and payors, and any delays in the trial's progress may negatively impact the company's potential for growth. Additionally, the fact that the trial has only added one private-practice site thus far raises concerns about the company's ability to recruit a sufficient number of participants and complete the trial in a timely manner, further adding to the negative outlook on Aclarion's stock.